RDTCF (Rapid Dose Therapeutics) Liabilities-to-Assets : 3.46 (As of Nov. 2024)

Rapid Dose Therapeutics Liabilities-to-Assets Chart

Rapid Dose Therapeutics Annual Data
	Trend	Sep15	Sep16	Sep17	Sep18	Feb19	Feb20	Feb21	Feb22	Feb23	Feb24
Liabilities-to-Assets		Get a 7-Day Free Trial					1.03	1.28	0.92	2.19	2.68

Rapid Dose Therapeutics Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Liabilities-to-Assets	Get a 7-Day Free Trial															3.27	2.68	2.82	3.19	3.46

Competitive Comparison of Rapid Dose Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Rapid Dose Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Liabilities-to-Assets falls into.

Rapid Dose Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Rapid Dose Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Feb. 2024 is calculated as:

Rapid Dose Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Nov. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics  (OTCPK:RDTCF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Rapid Dose Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics Business Description